RenovoRx Secures $12M Investment to Revolutionize Precision Oncology Therapies

RenovoRx (Nasdaq: RNXT) is thrilled to announce the successful raise of $12,000,000 in our latest funding round, marking a significant milestone in our mission to revolutionize precision oncology.

As a pioneering life sciences company dedicated to improving therapeutic outcomes for cancer patients, RenovoRx is at the forefront of innovation with our patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform.

This groundbreaking technology is designed to deliver targeted therapeutic agents directly to tumor sites by precisely crossing the arterial wall, thereby bathing the tumors in treatment while potentially reducing the toxic side effects associated with traditional systemic intravenous therapies.

The capital raised will primarily support the ongoing development and clinical evaluation of our Phase III lead product candidate, a novel oncology drug-device combination product that leverages the FDA-cleared RenovoCath® for intra-arterial infusion of gemcitabine HCl.

This candidate is currently under investigation under a U.S. investigational new drug application regulated by FDA’s 21 CFR 312 pathway for the treatment of locally advanced pancreatic cancer (LAPC).

In addition to accelerating clinical trials, this funding will facilitate the exploration of new commercialization strategies utilizing our TAMP technology and the RenovoCath platform as a stand-alone device.

This commitment to transformative innovation echoes our pledge to change the current paradigm of cancer care.

By harnessing cutting-edge science and strategic investment, RenovoRx continues to push boundaries in oncology, ultimately striving to deliver safer, more effective cancer treatments and improve patient quality of life.